"Such so-called dampening immunomodulators, which slow down an excessive immune response, could come onto the market more in the near
future. Vfa spokesman Hömke points to several funds that are in phase III and which, if the positive interim results are confirmed, could be submitted for approval in the coming months. These include the medicines MK-7110 from MSD, Leronlimab from CytoDyn and siltuximab from Eusa Pharma."

Insert-tag-herehttps://www.tagesschau.de/wirtschaft/technolo...t-101.html

Read More: https://investorshangout.com/post/view?id=612...z6u6edFF4g

translated from German